Oman MOH Pharmaceutical Registration & Import Rules

Oman MOH: The Regulator

The Ministry of Health (MOH) is Oman's national health authority. The Directorate General of Pharmaceutical Affairs and Drug Control (DGPA&DC) is responsible for pharmaceutical regulation, including product registration, import controls, and market surveillance.

Oman MOH's core functions:

• Product registration and marketing authorization
• Inspecting manufacturing facilities (GMP audits)
• Issuing import and export permits
• Pharmacovigilance and post-market surveillance
• Clinical trial authorization
• Pricing approval
• Licensing of pharmacies and drug outlets

MOH is headquartered in Muscat, with a growing electronic submission system called the MOH e-System. While less sophisticated than Qatar's or the UAE's systems, Oman has made significant progress in digitization. Paper submissions are still accepted but being phased out.

Registration Pathways & Product Categories

Oman MOH offers multiple registration pathways, with the GCC Common Registration File being the most strategic.

Pathway 1: Full Registration (New Chemical Entities / NCEs)

Full clinical trial data required. Timeline: 9-12 months. Oman is a moderate market for innovative products.

Pathway 2: Abridged Registration (Generic Products)

Requires bioequivalence data. The most common pathway for imports. Timeline: 6-9 months.

Pathway 3: GCC Common Registration File (CRF) - Recommended

This is the strategic pathway for Oman. One dossier reviewed by GCC committee leads to registration in Oman plus other GCC states. Oman is an enthusiastic participant in the GCC CRF. Timeline: 8-12 months for GCC review plus 1-3 months for national registration.

Pathway 4: WHO PQ Recognition (Fast-Track)

Products with WHO Prequalification receive priority review. Timeline: 4-6 months.

Pathway 5: SRA Recognition

Products approved by US FDA, EMA, Health Canada, TGA, PMDA, or MHRA receive accelerated review. Timeline: 3-5 months. Highly recommended.

Pathway 6: Locally Manufactured Products

Products manufactured in Oman receive priority processing (3-5 months) and government procurement preferences. Limited local manufacturing capacity but growing.

Prerequisites: What You Need Before Applying

Before submitting to Oman MOH, ensure these items are in place.

• Appoint a Local Agent/Distributor: Foreign manufacturers must appoint an Omani company with a valid MOH import license. Unlike Kuwait or Qatar, Oman does not require majority local ownership—100% foreign ownership is permitted in certain sectors, but most distributors are Omani-owned.
• Execute a Power of Attorney (PoA): A notarized document authorizing your local agent. Must be legalized at the Omani embassy.
• Obtain a Certificate of Pharmaceutical Product (CPP): Issued by your home regulator. Must be in WHO format, less than 2 years old, and legalized.
• Prepare Your Dossier in CTD Format: Oman MOH follows CTD format (Modules 1-5). Electronic submission preferred.
• WHO PQ or SRA Approval (if available): The single most valuable document for accelerated registration.
• Product Samples: Required for MOH laboratory testing in Muscat.

Step-by-Step Registration Process

Here's the actual process for registering with Oman MOH. It's one of the more straightforward processes in the GCC.

Step 1: Appoint a Local Agent

Sign an agreement with an Omani importer. Verify their MOH license and their experience with product registration and government tenders.

Step 2: Execute and Legalize Power of Attorney

Draft PoA, notarize, legalize at Omani embassy. No Arabic translation required for the PoA itself. This takes 2-3 weeks.

Step 3: Prepare Your CTD Dossier

Compile CTD dossier (Modules 1-5) in PDF format. Oman's e-System accepts electronic submissions.

Step 4: Pre-Submission Meeting (Optional but Recommended)

Your agent can request a meeting with MOH evaluators. Oman's MOH is accessible, and this meeting can clarify requirements and build relationships.

Step 5: Online Submission via MOH e-System

Your agent uploads the dossier, pays the application fee (OMR 50-150/$130-390), and receives an acknowledgement.

Step 6: Administrative Screening (2-4 weeks)

MOH checks for completeness, legalization, and format. Deficiency letters add 2-3 weeks per cycle. Oman is generally efficient.

Step 7: Scientific Evaluation (4-8 months)

MOH evaluators review quality, bioequivalence (if applicable), and labeling. Queries issued via e-System. You have 60 days to respond.

Step 8: GCC CRF Verification (if applicable - 1-2 months)

If using GCC Common Registration File, MOH coordinates with other GCC regulators.

Step 9: Laboratory Testing (1-2 months)

MOH's quality control laboratory in Muscat tests product samples. Failure = rejection.

Step 10: GMP Inspection (If Required)

MOH accepts WHO PQ, SRA inspections, or their own inspection. SRA approval typically waives inspection.

Step 11: Pricing Approval (1-2 months)

MOH sets the maximum selling price. See pricing section below.

Step 12: MOH Drug Registration Committee Approval (3-5 weeks)

Final approval and certificate issuance.

Dossier Requirements: The MOH CTD Format

Oman MOH follows CTD format (Modules 1-5), aligned with GCC and ICH standards.

Module 1: Administrative Information (Oman-Specific)

• Application letter on manufacturer letterhead (English)
• Cover letter from Omani agent
• Power of Attorney (legalized)
• Certificate of Pharmaceutical Product (WHO format, legalized, less than 2 years old)
• GMP Certificate (legalized)
• Free Sale Certificate
• Manufacturing license
• Labeling and package insert (English and Arabic, Arabic preferred for patient-facing text)
• WHO PQ certificate or SRA approval (if available)

Module 2: Summaries

Module 3: Quality

• Stability data: Oman has a hot desert climate with high humidity on the coast. Zone IV data is recommended.

Module 4: Nonclinical (NCEs only)

Module 5: Clinical/Bioequivalence

• Bioequivalence study report or WHO PQ certificate

Local Agent Requirements: The Local Representative

Oman's local agent requirements are more flexible than other GCC states.

What Your Omani Agent Must Have:

• Valid MOH pharmaceutical import license
• Physical warehouse in Muscat or other major city (Sohar, Salalah)
• Qualified pharmacist on staff
• Experience with MOH registration and government tender participation
• Cold chain capability (for temperature-sensitive products)

Ownership Flexibility:

• No majority local ownership requirement. Unlike Kuwait (51%) and Qatar (51%), Oman permits 100% foreign ownership in many sectors, including pharmaceutical distribution (subject to conditions).
• Most distributors are Omani-owned, but foreign-owned distribution companies are possible.
• This makes Oman more accessible than Kuwait or Qatar for foreign manufacturers who want more control.

Selecting Your Agent:

• Oman has approximately 15-20 licensed pharmaceutical importers
• Key players include: Muscat Pharmacy, Al Hayat International, New Medical Center, and various private importers
• Choose an agent with experience in your therapeutic category and a track record of successful MOH registrations
• Ask about their government tender experience—winning tenders is essential for volume

Pricing Regulations: The MOH Pricing System

Oman has a structured pricing system that is more transparent than Kuwait's but less automated than Saudi Arabia's.

How Oman's Pricing Works:

1. After scientific approval, your agent submits a pricing application to MOH.
2. You propose a Maximum Selling Price (MSP) to the pharmacy.
3. MOH reviews your proposal against:
   • GCC reference pricing: Prices in Saudi Arabia, UAE, Kuwait, Qatar, Bahrain
   • Country of origin price: Price in the manufacturer's home market
   • Therapeutic reference pricing: Prices of similar products in Oman
   • Public health importance
4. MOH approves a fixed MSP.

Key Pricing Realities:

• Oman has moderate prices—generally lower than Qatar and the UAE, comparable to or slightly higher than Saudi Arabia.
• Generics must be priced 20-25% below originators.
• Prices are fixed but can be reviewed annually. Unlike Kuwait's rigid system, Oman allows annual price adjustments with justification.
• Government tenders negotiate discounts below the MSP.

Pricing Timeline:

• Standard: 1-2 months
• Priority (for essential medicines): 3-4 weeks

GMP Compliance & Facility Inspections

Oman MOH's GMP requirements are aligned with WHO GMP and GCC standards.

GMP Evidence MOH Accepts:

• WHO Prequalification (highest acceptance - waives inspection)
• SRA inspection (US FDA, EMA, Health Canada, TGA, PMDA, MHRA) within last 2-3 years
• GCC joint inspection
• MOH-conducted inspection (if no other evidence)

When Does MOH Conduct Its Own Inspection?

• First-time registration without WHO PQ or SRA evidence
• Suspected GMP issues
• High-risk products (injectables, biologics, sterile products)

Inspection Process:

1. MOH notifies your agent (6-8 weeks notice)
2. Fee: OMR 3,000-5,000 ($7,800-13,000) plus travel expenses
3. Inspectors visit for 3-4 days
4. CAPA plan required for findings

Costs, Timelines & Budget Planning

Oman offers good value—moderate costs with reasonable timelines.

Official MOH Fees (Approximate)

• Application fee: OMR 50-150 ($130-390)
• Evaluation fee: OMR 100-300 ($260-780)
• Registration certificate: OMR 50-150 ($130-390)
• Annual retention fee: OMR 30-100 ($78-260) per product
• Import permit fee: OMR 10-20 ($26-52) per shipment

Third-Party Costs

• Regulatory consultant fees: $7,000-15,000 per product
• Document legalization: $1,000-2,000
• GMP inspection (if required): $10,000-15,000 plus travel
• Bioequivalence study: $50,000-150,000 if new study needed
• Stability studies: $10,000-25,000
• Local agent fees: $5,000-12,000 annually

Total Estimated Cost Per Product:

• Generic with SRA approval (fastest): $10,000-20,000
• Generic with WHO PQ: $12,000-22,000
• Standard generic (well-prepared): $15,000-25,000
• Innovative product (NCE): $25,000-50,000+

Timelines:

• SRA Fast-Track: 3-5 months
• WHO PQ Fast-Track: 4-6 months
• GCC Common Registration File: 8-12 months (regional) plus 1-3 months national
• Standard generic (well-prepared): 6-9 months
• Standard generic (poor dossier): 9-12 months

The Tender System: Oman's Central Procurement

Oman's public sector pharmaceutical procurement is centralized through the Oman Pharmaceutical Procurement Company (OPPC) under the Ministry of Health.

How Omani Tenders Work:

1. MOH identifies product requirements and issues tender announcements.
2. Eligible suppliers (registered importers with MOH-registered products) submit bids through their local agent.
3. The Tender Committee evaluates bids based on:
   • Price (40-50% weight) - Competitive pricing required
   • Product quality (30-40% weight) - SRA/WHO PQ strongly preferred
   • Supplier reliability (20% weight) - Previous performance, delivery history
   • Local presence (bonus) - Warehousing in Oman
4. Winning bids receive contracts for specific quantities, delivered to MOH central warehouses.

Public vs. Private Sector:

• Public sector (MOH tenders): 70-75% of market. Lower margins but predictable volume.
• Private sector: 25-30% of market. Higher margins but smaller volumes. Private hospitals and pharmacies purchase through distributors.

GCC Common Registration File: The Preferred Pathway

Oman is one of the most enthusiastic participants in the GCC Common Registration File. This should be your default pathway if targeting multiple GCC markets.

Why Use GCC CRF for Oman:

• Oman's MOH trusts the GCC joint assessment
• Faster than standalone registration for the first product
• One dossier provides access to all six GCC markets
• Lower total cost than sequential registrations

Using Oman as GCC CRF Reference State:

Oman can serve as your reference state for the GCC CRF. Benefits include:

• Oman's MOH is accessible and cooperative
• Lower costs than using Saudi Arabia or UAE as reference
• Faster processing than Kuwait

Common Pitfalls & Rejection Reasons

• Invalid or Expired CPP: Less than 2 years old, WHO format required
• Missing Legalization: All foreign documents must be legalized at Omani embassy
• Incorrect Reference Product for BE: Must use Oman-registered reference
• Inadequate Stability Data: Zone IV (hot/humid) recommended
• GMP Certificate Issues: Expired or not from recognized authority
• No Local Agent Agreement: Valid agent license must be on file
• Product Sample Fails MOH Testing: Immediate rejection
• Unreasonable Pricing Proposal: Too high compared to GCC reference countries
• Incomplete Dossier (Missing Modules): MOH requires all 5 CTD modules
• Missing Arabic on Labeling: Patient-facing labeling must include Arabic

Post-Registration Obligations & Renewal

• Annual Retention Fees: Payable each year via MOH e-System
• Variations: Changes require MOH approval; timeline 2-4 months
• Renewal: Every 5 years, start 6-9 months before expiry
• Pharmacovigilance: Your agent must report adverse events to MOH; PSURs every 2 years
• Price Maintenance: Annual price reviews permitted with justification
• Post-Market Surveillance: MOH samples products; failures lead to recalls
• Tender participation: Maintain pre-qualification status and bid regularly

Oman vs. Other GCC Markets

The strategic takeaway: Oman is the best entry-level GCC market. Lower barriers, lower costs, and a pragmatic regulator make it ideal for first-time GCC entrants. Use Oman to establish your GCC footprint, then expand to UAE or Saudi Arabia.

Conclusion: Your Oman Entry Strategy

Oman is the GCC's hidden gem for pharmaceutical exporters. The market is accessible, the regulator is pragmatic, and the costs are reasonable. For manufacturers looking to establish a GCC footprint without the complexity of Saudi Arabia or the costs of Qatar, Oman is the ideal starting point.

Your Oman registration checklist:

• ✓ Find an Omani agent with MOH license and tender experience
• ✓ Obtain SRA approval (US FDA, EMA) or WHO PQ for your product
• ✓ Execute and legalize Power of Attorney (no Arabic translation needed)
• ✓ Obtain valid CPP (WHO format, less than 2 years old)
• ✓ Prepare CTD dossier (English only, no Arabic translations required)
• ✓ Budget $15,000-25,000 per product
• ✓ Plan for 6-9 months for registration (3-5 months with SRA approval)
• ✓ Use the GCC Common Registration File for regional expansion
• ✓ Develop competitive pricing aligned with GCC reference countries
• ✓ Pursue MOH tender pre-qualification for volume
• ✓ Hire a local regulatory consultant with MOH relationships
• ✓ Consider establishing your own distribution company (100% foreign ownership possible)
• ✓ Use Oman as your GCC launchpad before expanding to larger markets

Is Oman worth it? Yes—for almost every pharmaceutical exporter targeting the GCC. The market is large enough (5 million people, growing), the regulatory barriers are moderate, and the costs are reasonable. Oman should be your first GCC market if you're new to the region, or a solid addition to your portfolio if you're already established in Saudi or the UAE.

Start with Oman. Register your product, build relationships with MOH, win tenders, and establish private distribution. Then use your Omani registration as a reference to expand to the UAE, Qatar, and Kuwait via the GCC CRF. Oman is the gateway to the GCC—accessible, pragmatic, and profitable.